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Postinfectious cough and pertussis in primary care
A respiratory infection is the most common cause of acute 
persistent cough and is the initiating event in almost 50% 
of cases.1 Cough persists for 2 weeks or more in around 
25% of patients with a common cold and in up to 50% 
when the illness is caused by Mycoplasma pneumoniae or 
Bordetella pertussis infection.2,3 Inﬂ u enza virus infection 
is also recognised as a cause of acute persistent cough.4 
The pathogenesis of acute persistent cough is frequently 
multifactorial.5 Transient airway inﬂ ammation is believed 
to be central to its development.5 This inﬂ ammation can 
be either or both intrathoracic or extrathoracic. When the 
inﬂ ammation involves the lower airway, cough is believed 
to be caused by mucous hypersecretion and impaired 
mucous clearance. Inﬂ ammation of the upper airway 
can also directly stimulate cough receptors or cough can 
be caused by the draining of secretions from inﬂ amed 
nasal and paranasal sinus mucosa into the hypopharynx 
and larynx. Gastro-oesophageal reﬂ ux can develop or be 
worsened as a result of vigorous coughing and, in turn, 
contribute to persistence of cough.5
Using quality of life as an outcome measure, Kay Wang 
and colleagues6 in The Lancet Respiratory Medicine show 
that montelukast was not an eﬀ ective treatment for 
acute persistent cough in the primary care setting. 
Quality of life was assessed with the Leicester Cough 
Questionnaire (LCQ), which was originally developed 
as a health-related quality of life measure for adults 
with chronic cough.7 The LCQ has subsequently been 
shown to be a valid measure for assessment of health 
status in patients with acute cough.8 In this context it 
is highly responsive to change.8 Using the change in 
LCQ total score that is the minimum change deemed 
clinically signiﬁ cant by adults with chronic cough, the 
investigators noted no eﬀ ect.9
Study power was adequate to show that montelukast 
is not eﬀ ective for the adult patient presenting to 
their general practitioner with undiﬀ erentiated 
acute persistent postinfectious cough. In view of the 
multifactorial nature of such cough, this ﬁ nding is not 
altogether unexpected. But what about the largest 
subgroup, namely patients with acute persistent cough 
secondary to B pertussis infection? In adolescents 
and adults with cough duration of 2 weeks or more 
presenting to primary care, between 12% and 52% will 
have evidence of recent B pertussis infection, irrespective 
of whether they were enrolled during an epidemic or 
non-epidemic interval.10 Evidence of recent B pertussis 
infection was present in 25% of participants in this study.
Exploratory analyses by Wang and colleagues of this 
subgroup with B pertussis infection showed a reduction 
in overall cough severity on a visual analogue scale. What 
should we do with this information? An absence of a 
statistically and clinically signiﬁ cant eﬀ ect of montelukast 
on cough related to B pertussis infection would add 
montelukast to the list of drugs (antihistamines, 
corticosteroids, pertussis immuno globulin, and sal-
butamol) for which no eﬃ  cacy against pertussis was 
evident in a recent systematic review of symptomatic 
treatment of cough in pertussis.11 However, because the 
analyses in this study of the eﬀ ect of montelukast on 
cough induced by B pertussis are exploratory, consignment 
of montelukast to the pertussis pharmaceutical scrap heap 
would seem premature, particularly because the published 
studies to date of treatments for pertussis are of fairly low 
quality.11 Also all ten of the trials included in the systematic 
review were in children, with most restricting eligibility 
to preschool-aged children admitted to hospital with 
pertussis.11 Thus Wang and colleagues’ trial is the ﬁ rst to 
use a robust study design, albeit with insuﬃ  cient power, 
to evaluate a treatment for pertussis in adults presenting 
to primary care.
With pertussis now recognised globally as a cause 
of acute persistent cough across the age range, 
evaluations of treatments for pertussis across the age 
and clinical ranges are also needed. Such studies should 
use the design features that resulted in this trial being 
of such high quality. Recruitment of participants into 
primary care trials of treatments for pertussis should 
be based on symptoms but not case deﬁ nitions. In 
developed countries pertussis outside the young infant 
age range is now predominantly a vaccine-modiﬁ ed 
disease. With the introduction of booster doses of 
pertussis vaccine to national immunisation schedules 
the diﬀ erence in clinical presentation of pertussis 
compared with other postinfectious cough illnesses is 
becoming increasingly subtle.12
The diagnostic test used to conﬁ rm recent B pertussis 
infection should be as non-invasive as possible. 
The oral ﬂ uid test used in this study to diagnose 
B pertussis infection is ideally suited to the primary care 
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Inhaled  β2-agonists alone or in combination with an 
inhaled corticosteroid are among the most commonly 
used treatments for patients with stable chronic 
obstructive pulmonary disease (COPD).1,2 However, 
variation in the  β2-adrenergic receptor gene (ADRB2) 
could aﬀ ect the treatment response to inhaled 
β2-agonists in COPD. Identiﬁ cation of gene variants that 
aﬀ ect the therapeutic response to inhaled β2-agonists 
could open up the possibility of establishing in advance 
which drugs might beneﬁ t the individual patient 
with COPD. So far studies assessing ADRB2 variants as 
determinants of response to bronchodilators have shown 
conﬂ icting results.3,4 Two recent trials assessing the eﬀ ect 
of ADRB2 variants on response to formoterol/budesonide 
and indacaterol did not identify a signiﬁ cant interaction 
between ADRB2 genotype and treatment response.5,6 
In The Lancet Respiratory Medicine, Klaus Rabe and 
colleagues7 report on ﬁ ndings from the hitherto largest 
study of ADRB2 variants as determinants of response to 
bronchodilators in COPD. Based on a prospective trial of 
5125 COPD patients, Rabe and colleagues identiﬁ ed that 
patients homozygous for the Arg16 variant in ADRB2 
have a reduced exacerbation risk in response to inhaled 
salmeterol compared with controls.7 Serving as a negative 
control, the study did not identify an eﬀ ect of the ADRB2 
genotype in response to inhaled tiotropium. These 
ﬁ ndings need conﬁ rmation in additional prospective 
studies, but suggest that  ADRB2 Arg16 might aﬀ ect the 
properties of inhaled salmeterol in patients with COPD. 
The exact mechanism underlying the lower exacer-
bation risk in response to salmeterol in patients homo-
zygous for Arg16 is not clear. The Arg16 variant is situated 
in the extracellular N-terminus of the β2-adrenergic 
receptor, which is involved in traﬃ  cking and membrane 
insertion of the receptor.8 The Arg16 variant has 
been associated with less downregulation of the 
β2-adrenergic receptor after exposure to isoproterenol 
in transfected cells and primary smooth muscle cells.9,10 
Rabe and colleagues speculate that this reduced degree 
of downregulation might allow salmeterol to provide 
increased bronchoprotection in Arg16 homozygotes 
compared with patients with Arg16Gly and Gly16Gly 
genotypes.7 Although less downregulation of the 
β2-adrenergic receptor in Arg16 seems to corroborate 
the ﬁ ndings, future studies are needed to further clarify 
the mechanism by which exacerbation outcomes after 
salmeterol might be aﬀ ected by Arg16 in ADRB2. 
The β2-adrenergic receptor has two major functions in 
human lung: it mediates smooth muscle relaxation and 
bronchodilation, and it mediates bronchoprotection 
setting.12 Making this assay available to the primary 
care clinician as well as the primary care clinical trialist 
should be a priority.
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